张力制表 2026年,减肥药赛道早已告别诺和诺德一家独大的旧格局。随着司美格鲁肽核心化合物专利到期,国内市场迎来全新竞争态势:信达生物玛仕度肽注射液III期临床试验成功达成主要终点,来凯医药、先为达生物等本土企业则加速冲刺港股IPO,试图在资本与市场的双重赛道抢占先机。 进入4月份,口服剂型的商业化落地,成为全球减肥药赛道的新焦点。4月1日,礼来旗下口服小分子GLP-1(胰高血糖素样肽-1)...
Source Link张力制表 2026年,减肥药赛道早已告别诺和诺德一家独大的旧格局。随着司美格鲁肽核心化合物专利到期,国内市场迎来全新竞争态势:信达生物玛仕度肽注射液III期临床试验成功达成主要终点,来凯医药、先为达生物等本土企业则加速冲刺港股IPO,试图在资本与市场的双重赛道抢占先机。 进入4月份,口服剂型的商业化落地,成为全球减肥药赛道的新焦点。4月1日,礼来旗下口服小分子GLP-1(胰高血糖素样肽-1)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.